These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37632002)

  • 1. BNT162b2 Elicited an Efficient Cell-Mediated Response against SARS-CoV-2 in Kidney Transplant Recipients and Common Variable Immunodeficiency Patients.
    La Civita E; Zannella C; Brusa S; Romano P; Schettino E; Salemi F; Carrano R; Gentile L; Punziano A; Lagnese G; Spadaro G; Franci G; Galdiero M; Terracciano D; Portella G; Loffredo S
    Viruses; 2023 Jul; 15(8):. PubMed ID: 37632002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
    Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
    J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated CD21
    Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
    J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
    Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
    Front Immunol; 2022; 13():907125. PubMed ID: 35784359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant.
    Del Mastro A; Picascia S; D'Apice L; Trovato M; Barba P; Di Biase I; Di Biase S; Laccetti M; Belli A; Amato G; Di Muro P; Credendino O; Picardi A; De Berardinis P; Del Pozzo G; Gianfrani C
    Viruses; 2023 May; 15(5):. PubMed ID: 37243218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients.
    Netti GS; Infante B; Troise D; Mercuri S; Panico M; Spadaccino F; Catalano V; Gigante M; Simone S; Pontrelli P; Gesualdo L; Ranieri E; Castellano G; Stallone G
    Am J Transplant; 2022 May; 22(5):1475-1482. PubMed ID: 35038362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency.
    Milota T; Smetanova J; Skotnicova A; Rataj M; Lastovicka J; Zelena H; Parackova Z; Fejtkova M; Kanderova V; Fronkova E; Rejlova K; Sediva A; Kalina T
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):306-314.e2. PubMed ID: 36379409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients.
    Pérez-Flores I; Juarez I; Aiffil Meneses AS; Lopez-Gomez A; Romero NC; Rodriguez-Cubillo B; Moreno de la Higuera MA; Peix-Jiménez B; Gonzalez-Garcia R; Baos-Muñoz E; Vilela AA; Gómez Del Moral M; Martínez-Naves E; Sanchez-Fructuoso AI
    Front Immunol; 2023; 14():1111569. PubMed ID: 36817489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
    Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients.
    Barrios Y; Franco A; Alava-Cruz C; Cuesta-Martin R; Camara C; Matheu V
    Allergol Immunopathol (Madr); 2022; 50(3):101-105. PubMed ID: 35527662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
    Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
    Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients.
    Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC
    Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-Specific CD4
    Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    Front Immunol; 2022; 13():827048. PubMed ID: 35237272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
    PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy.
    Antolí A; Rocamora-Blanch G; Framil M; Mas-Bosch V; Navarro S; Bermudez C; Martinez-Yelamos S; Dopico E; Calatayud L; Garcia-Muñoz N; Hernández-Benítez LH; Riera-Mestre A; Bas J; Masuet-Aumatell C; Rigo-Bonnin R; Morandeira F; Solanich X
    Front Immunol; 2022; 13():895209. PubMed ID: 35572562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients.
    Graninger M; Stumpf J; Bond G; Görzer I; Springer DN; Kessel F; Kröger H; Frank K; Tonn T; Hugo C; Puchhammer-Stöckl E
    J Clin Virol; 2023 May; 162():105428. PubMed ID: 36989730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls.
    Yanis A; Haddadin Z; Spieker AJ; Waqfi D; Rankin DA; Talj R; Thomas L; Birdwell KA; Ezzell L; Blair M; Eason J; Varjabedian R; Warren CM; Nochowicz CH; Olson EC; Simmons JD; Yoder S; Guy M; Thomsen I; Chappell JD; Kalams SA; Halasa NB
    Transpl Infect Dis; 2022 Feb; 24(1):e13772. PubMed ID: 34905653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
    Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2021; 12():815404. PubMed ID: 35126372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.